BRIEF published on 01/29/2026 at 00:26, 1 month 25 days ago GenSight Biologics publie les résultats de l'EGM Assemblée Générale Extraordinaire Actionnaires Augmentation De Capital GenSight Biologics Autorisations Financières
PRESS RELEASE published on 01/29/2026 at 00:21, 1 month 25 days ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 2 months 25 days ago GenSight Biologics finalise une levée de fonds de 2,9 millions d'euros. Actionnaires Thérapie Génique Collecte De Fonds Maladies De La Rétine Usage Compassionnel
BRIEF published on 12/29/2025 at 08:05, 2 months 25 days ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
PRESS RELEASE published on 12/29/2025 at 08:00, 2 months 25 days ago Informations privilégiées / Autres communiqués GenSight Biologics réalise une levée de fonds de près de €2,9 millions d’euros pour développer des thérapies géniques innovantes. La société vise le traitement des maladies neurodégénératives de la rétine Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Rétine
PRESS RELEASE published on 12/29/2025 at 08:00, 2 months 25 days ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 12/22/2025 at 07:05, 3 months 1 day ago GenSight Biologics Receives Compassionate Use Authorization for GS010/LUMEVOQ® in France Gene Therapy Rare Diseases Compassionate Use LHON Treatment ANSM Approval
BRIEF published on 12/22/2025 at 07:05, 3 months 1 day ago GenSight Biologics obtient une autorisation d'usage compassionnel pour GS010/LUMEVOQ® en France Thérapie Génique Maladies Rares Usage Compassionnel Traitement De La LHON Approbation ANSM
BRIEF published on 12/22/2025 at 07:05, 3 months 1 day ago Délivrance d'une autorisation d'accès compassionnel pour GS010/LUMEVOQ® Thérapie Génique GenSight Biologics NOHL Accès Compassionnel ANSM
BRIEF published on 12/22/2025 at 07:05, 3 months 1 day ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
Published on 03/23/2026 at 14:05, 2 hours 4 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 2 hours 9 minutes ago BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 3 hours 4 minutes ago SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 3 hours 37 minutes ago Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 3 hours 39 minutes ago Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 15:05, 1 hour 3 minutes ago Heidrick & Struggles Launches Heidrick Immersive, an AI-Enhanced Platform for Observing Leadership in Motion
Published on 03/23/2026 at 14:41, 1 hour 27 minutes ago CEWE increases dividend for 17 consecutive years
Published on 03/23/2026 at 14:30, 1 hour 38 minutes ago Solvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability Performance
Published on 03/23/2026 at 14:30, 1 hour 39 minutes ago Belvilla Expands in Germany with Hambachtal Holiday Park in Oberhambach
Published on 03/23/2026 at 14:24, 1 hour 45 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 03/23/2026 at 08:10, 7 hours 59 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 21 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 21 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 21 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 21 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
